东阳光药抗纤维化新药临床数据亮相国际峰会

Group 1 - The ninth IPF summit in Boston focused on the latest breakthroughs and research progress in IPF treatment, with Dongyangguang Pharmaceutical presenting key data on its self-developed anti-fibrotic drug HEC585 [1] - HEC585 is the first domestically developed original drug for IPF to enter Phase III clinical trials, featuring a unique multi-target mechanism that inhibits TNF-α and TGF-β1 release [1][2] - The Phase II clinical trial included 224 IPF patients, showing that the 200mg group had a minimal decline in FVC of only 3.3mL compared to over 80mL improvement in the placebo group, with a 96% rate of delaying lung function decline [2] Group 2 - IPF is a high-mortality rare disease with a median survival of only 2-3 years, and currently, only two drugs are approved globally, indicating unmet clinical needs [2] - HEC585 demonstrates "Best-in-class" potential due to its once-daily dosing and significant efficacy and safety advantages, with strong drug-like properties confirmed in preclinical studies [2] - Dongyangguang Pharmaceutical has a dual internationalization strategy, with 68 drugs approved in Europe and the US, and HEC585 is positioned as a key candidate for global commercialization [3][4] Group 3 - The company has successfully challenged original drug patents in the US and submitted a listing application for insulin, aiming to be the first domestic company to market this product in the US [3] - HEC585 has the potential for multiple indications, including progressive fibrosing interstitial lung disease and hepatitis B liver fibrosis, enhancing its overseas licensing value [3][4] - The ongoing development of HEC585 signifies Dongyangguang Pharmaceutical's innovation capabilities and global strategic layout in the field of fibrotic diseases, with expectations for future market entry and international collaboration [4]